Rigel’s EPS Plunges as Revenue Misses and Shorts Linger

Forward-Looking Analysis

Analysts project Rigel Pharmaceuticals will report earnings per share (EPS) of $0.09 for the second quarter of 2026, a significant decline from the $0.44 EPS recorded in the previous quarter. Revenue is expected to contract to $55.27 million, down from the $58.82 million reported in Q1 2026 and below the prior quarter's estimated $62.40 million. This forecast reflects a continued trend of shrinking top-line performance, as Q1 revenue also missed consensus estimates by approximately $3.58 million. The projected net income for the upcoming quarter is not explicitly detailed in current analyst summaries, though the sharp drop in EPS suggests margin pressures or increased operational costs relative to the $8.65 million net income achieved in Q1. Valuation metrics indicate the stock trades at a low Price-to-Earnings ratio of 2.04, significantly below the medical sector average of 27.59, suggesting market skepticism regarding future profitability growth. While long-term earnings are projected to grow by 7.41% over the coming year, the immediate quarterly outlook points to continued contraction. Analyst consensus remains a "Hold" with an average price target of $54.50, implying substantial upside from the current trading level of approximately $38.22, yet short interest remains high at 19.06% of the float, indicating bearish sentiment among some investors despite recent decreases in short positions.

Historical Performance Review

Rigel Pharmaceuticals delivered a challenging Q1 2026 performance, reporting revenue of $58.82 million, which missed analyst estimates of $62.40 million. Net income stood at $8.65 million, a sharp decrease from the $268.06 million recorded in the preceding quarter, despite a reported gross profit of $54.21 million. Earnings per share came in at $0.47, significantly below the consensus estimate of $0.80, resulting in a negative earnings surprise of approximately 41-44%. The company maintained a healthy EBITDA margin of 43.46% with $126.99 million in trailing EBITDA, yet the substantial drop in net income highlights significant non-operational or one-time factors impacting the bottom line during this period.

Additional News

Rigel Pharmaceuticals recently announced its conference call and webcast to report second-quarter 2026 financial results, scheduled for early August 2026. In leadership developments, the company appointed Alison L. Hannah, M.D., as Chief Medical Officer on July 1, 2026, strengthening its executive team. Additionally, Rigel announced inducement grants under NASDAQ Listing Rule 5635(c)(4) on July 7, 2026, likely aimed at retaining key talent. The company continues to focus on its lead product, fostamatinib (Tavalisse®), for chronic immune thrombocytopenia, while advancing clinical programs for IgA nephropathy and other immune-mediated conditions. As of August 1, 2026, Rigel employs 174 individuals. Recent market analysis notes a 1-10 reverse split occurred in June 2024, affecting share structure. Insider activity in the past three months showed net selling, with insiders selling $160,425 in stock while buying none, contrasting with high institutional ownership of 66.23%.

Summary & Outlook

Rigel Pharmaceuticals exhibits mixed financial health, characterized by contracting revenue and a dramatic year-over-year drop in net income, though EBITDA margins remain robust. The primary risk factor is the persistent revenue miss and downward EPS trajectory, exacerbated by high short interest and insider selling. However, the company’s strong institutional backing and low valuation multiples suggest potential undervaluation. Catalysts include the clinical advancement of fostamatinib in new indications and leadership stabilization with the new CMO. While near-term earnings face headwinds, the long-term growth projection of 7.41% and significant analyst price target upside suggest a cautiously neutral-to-bullish long-term outlook, provided the company can reverse its revenue decline and stabilize profitability in upcoming quarters.